Claims for Patent: 10,016,451

Summary for Patent: 10,016,451

Title:	Nucleic acid nanoparticles and uses therefor
Abstract:	The present invention provides nanoparticle compositions including one or more nucleic acids. The present invention achieves delivery (particularly transdermal delivery) of such nucleic acids without the need for nucleic acid modification, or for use of chemical or mechanical abrasion or disruption of skin.
Inventor(s):	Edelson; Jonathan (Scarsdale, NY), Kotyla; Timothy (Lowell, MA), Zhang; Boke (Brighton, MA)
Assignee:	Anterios, Inc. (New York, NY)
Application Number:	12/671,693
Patent Claims:	1. A method, comprising the steps of: providing a composition comprising a nanoemulsion comprising particles in a dispersion medium, wherein the nanoemulsion was generated by exposure to high shear force; wherein: the nanoemulsion comprises an oil and a surfactant; the majority of particles in the dispersion medium are nanoparticles that have diameters between approximately 10 nanometers and approximately 300 nanometers; the particles comprise at least one nucleic acid of length up to 30 nucleotides that has biological activity in the skin, subcutaneous tissue, contiguous muscle, or distant tissue; wherein the at least one nucleic acid comprises a thymidine dinucleotide, a phosphorylated thymidine dinucleotide (pTT), or a combination of both; and the at least one nucleic acid does not induce immune reactions; and administering the composition to the skin of a subject so that transdermal delivery of the nucleic acid is achieved; and wherein at least 95% of the nucleic acid penetrates the skin. 2. The method of claim 1, wherein the composition is administered transdermally using an adhesive patch. 3. The method of claim 1, wherein the composition is administered transdermally using a spatula, swab, syringe without a needle, gloved finger, or unprotected finger. 4. The method of claim 1, wherein the composition is administered transdermally using a device that permits application of the composition to a target site on the skin without applying the composition to non-target sites of the skin. 5. The method of claim 1, wherein the composition is administered so that a cosmetic effect is achieved. 6. The method of claim 5, wherein the cosmetic effect is or comprises tanning of the skin. 7. The method of claim 1, wherein the biological activity is activity on skin structures. 8. The method of claim 1, wherein the biological activity of the nucleic acid is not impaired by the nanoparticles. 9. The method of claim 1, wherein the majority of particles have a range of diameters between approximately 10 nanometers and approximately 200 nanometers. 10. The method of claim 9, wherein the majority of particles have a range of diameters between approximately 10 nanometers and approximately 120 nanometers. 11. The method of claim 10, wherein the majority of particles have a range of diameters between approximately 10 nanometers and approximately 50 nanometers. 12. The method of claim 1, wherein the oil is selected from the group consisting of saturated and unsaturated almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils; butyl stearate; caprylic triglyceride; capric triglyceride; cyclomethicone; diethyl sebacate; dimethicone 360; isopropyl myristate; medium chain triglycerides; mineral oil; octyldodecanol; oleyl alcohol; and silicone oil; and wherein the surfactant is selected from the group consisting of phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid monoglycerides; fatty acid diglycerides; fatty acid amides; sorbitan trioleate (SP AN.RTM.85) glycocholate; sorbitan monolaurate (SPAN.RTM.20); polysorbate 20 (TWEEN.RTM.20); polysorbate 60 (TWEEN.RTM.60); polysorbate 65 (TWEEN.RTM.65); polysorbate 80 (TWEEN.RTM.80); polysorbate 85 (TWEEN.RTM.85); polyoxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipids; synthetic and/or natural detergents having high surfactant properties; deoxycholates; cyclodextrins; chaotropic salts; and ion pairing agents. 13. The method of claim 1, wherein the nanoemulsion comprises a pre-mix of a medium chain triglyceride, Tween, water, and the nucleic acid. 14. The method of claim 1, wherein the nucleic acid is encapsulated within the nanoparticles. 15. The method of claim 1, wherein the nucleic acid is associated with the particle surface. 16. The method of claim 1, wherein the nanoemulsion can penetrate skin without altering or changing the skin. 17. The method of claim 1, wherein the nanoemulsion can penetrate skin without the use of skin permeation enhancers or abrasives. 18. The method of claim 1, wherein the nanoemulsion can penetrate the top layer of skin without the use of skin permeation enhancers or abrasives. 19. The method of claim 1, wherein the oil and surfactant are present in a ratio ranging from 0.5-2.0. 20. The method of claim 1, wherein the percent of oil in the nanoemulsion ranges from 1%-30%. 21. The method of claim 1, wherein the percent of oil in the nanoemulsion ranges from approximately 5% to approximately 9%. 22. The method of claim 1, wherein the percent of surfactant in the nanoemulsion ranges from 1%-30%. 23. The method of claim 1, wherein the percent of surfactant in the nanoemulsion ranges from approximately 5% to approximately 9%. 24. The method of claim 1, wherein the nanoemulsion is substantially free of toxic solvents. 25. The method of claim 1, wherein the nanoparticles further comprise an additional biologically active agent. 26. The method of claim 25, wherein the additional biologically active agent is a chemotherapeutic agent. 27. The method of claim 26, wherein the additional biologically active agent is dacarbazine. 28. The method of claim 1, wherein the composition comprises a second population of particles comprising a chemotherapeutic agent. 29. The method of claim 28, wherein the chemotherapeutic agent is dacarbazine. 30. The method of claim 1, wherein the at least one nucleic acid is a single-stranded nucleic acid. 31. The method of claim 1, wherein the nanoemulsion comprises oily particles dispersed within an aqueous medium. 32. The method of claim 1, wherein the nanoemulsion comprises aqueous particles dispersed within an oily medium.

Details for Patent 10,016,451

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder	Powder	125696	01/31/2020		2027-05-31